drugset / Trial / NCT03127618

Lorlatinib - PF-06463922

NCT03127618

Expanded access Approved for marketing Pfizer

Summary

Lorlatinib expanded access program

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Background Lorlatinib Small molecule

Indications

No indication recorded.